Show simple item record

dc.contributor.authorHenares, Desirée
dc.contributor.authorRocafort, Muntsa
dc.contributor.authorBrotons, Pedro
dc.contributor.authorDe Sevilla, Mariona F.
dc.contributor.authorMira, Alex
dc.contributor.authorLaunes, Cristian
dc.contributor.authorCabrera-Rubio, Raul
dc.contributor.authorMuñoz-Almagro, Carmen
dc.date.accessioned2021-11-04T15:32:55Z
dc.date.available2021-11-04T15:32:55Z
dc.date.issued2021
dc.identifier.citationHenares, Desiree; Rocafort, Muntsa; Brotons, Pedro [et al.]. Rapid increase of oral bacteria in nasopharyngeal microbiota after antibiotic treatment in children with invasive pneumococcal disease. Frontiers in Cellular and Infection Microbiology, 2021, 11, 744727. Disponible en: <https://www.frontiersin.org/articles/10.3389/fcimb.2021.744727/full>. Fecha de acceso: 4 nov. 2021. DOI: 10.3389/fcimb.2021.744727ca
dc.identifier.issn2235-2988ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2908
dc.description.abstractIntroduction: Antibiotics are commonly prescribed to young children for treating bacterial infections such as invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. Despite the obvious benefits of antibiotics, little is known about their possible side effects on children’s nasopharyngeal microbiota. In other ecological niches, antibiotics have been described to perturb the balanced microbiota with short- and long-term effects on children’s health. The present study aims to evaluate and compare the nasopharyngeal microbiota of children with IPD and different degree of antibiotic exposure. Methods: We investigated differences in nasopharyngeal microbiota of two groups of children <18 years with IPD: children not exposed to antibiotics before sample collection (n=27) compared to children previously exposed (n=54). Epidemiological/clinical data were collected from subjects, and microbiota was characterized by Illumina sequencing of V3-V4 amplicons of the 16S rRNA gene. Results: Main epidemiological/clinical factors were similar across groups. Antibiotic-exposed patients were treated during a median of 4 days (IQR: 3–6) with at least one beta-lactam (100.0%). Higher bacterial richness and diversity were found in the group exposed to antibiotics. Different streptococcal amplicon sequence variants (ASVs) were differentially abundant across groups: antibiotic use was associated to lower relative abundances of Streptococcus ASV2 and Streptococcus ASV11 (phylogenetically close to S. pneumoniae), and higher relative abundances of Streptococcus ASV3 and Streptococcus ASV12 (phylogenetically close to viridans group streptococci). ASVs assigned to typical bacteria from the oral cavity, including Veillonella, Alloprevotella, Porphyromonas, Granulicatella, or Capnocytophaga, were associated to the antibiotic-exposed group. Common nosocomial genera such as Staphylococcus, Acinetobacter, and Pseudomonas were also enriched in the group exposed to antibiotics. Conclusion: Our results point toward a reduction of S. pneumoniae abundance on the nasopharynx of children with IPD after antibiotic treatment and a short-term repopulation of this altered niche by oral and nosocomial bacteria. Future research studies will have to evaluate the clinical implications of these findings and if these populations would benefit from the probiotic/prebiotic administration or even from the improvement on oral hygiene practices frequently neglected among hospitalized children.en
dc.format.extent12ca
dc.language.isoengca
dc.publisherFrontiers Mediaca
dc.relation.ispartofFrontiers in Cellular and Infection Microbiologyca
dc.relation.ispartofseries11;
dc.rights© 2021 Henares, Rocafort, Brotons, de Sevilla, Mira, Launes, Cabrera-Rubio and Muñoz-Almagro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherNensca
dc.subject.otherMicrobiota nasofaríngiaca
dc.subject.otherMalaltia pneumocòcica invasiva (IPD)ca
dc.subject.otherAntibiòticsca
dc.subject.otherBacteris oralsca
dc.subject.otherBacteris nosocomialsca
dc.subject.otherNiñoses
dc.subject.otherMicrobiota nasofaríngeaes
dc.subject.otherEnfermedad neumocócica invasiva (ENI)es
dc.subject.otherAntibióticoses
dc.subject.otherBacterias oraleses
dc.subject.otherBacterias nosocomialeses
dc.subject.otherChildrenen
dc.subject.otherNasopharyngeal microbiotaen
dc.subject.otherInvasive pneumococcal disease (IPD)en
dc.subject.otherAntibioticsen
dc.subject.otherOral bacteriaen
dc.subject.otherNosocomial bacteriaen
dc.titleRapid increase of oral bacteria in nasopharyngeal microbiota after antibiotic treatment in children with invasive pneumococcal diseaseen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.9ca
dc.identifier.doihttps://dx.doi.org/10.3389/fcimb.2021.744727ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2021 Henares, Rocafort, Brotons, de Sevilla, Mira, Launes, Cabrera-Rubio and Muñoz-Almagro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint